Periodontal Disease: Classification, Systemic Connections, Diagnostics, and Treatment

Ronav Korat

Abstract

Periodontal disease refers to a spectrum of chronic inflammatory conditions that damage the tissues supporting the teeth, beginning with mild gingival swelling and potentially advancing to severe forms such as chronic or aggressive periodontitis. Triggered primarily by dental plaque accumulation, this condition leads to loss of tissue attachment, deterioration of alveolar bone, and ultimately, tooth loss. Emerging research has established meaningful connections between periodontal disease and systemic conditions — including cardiovascular disease and dementia — mediated by shared immune responses and overlapping microbial involvement. Elevated systemic inflammatory markers alongside the detection of oral bacteria in distal organs lend further support to these associations. Advances in diagnostic tools — including radiographic imaging, salivary biomarker analysis, and molecular genetic screening — have improved the accuracy of early identification and longitudinal disease monitoring. Treatment approaches combining mechanical debridement with antimicrobial therapy and surgical intervention have demonstrated measurable reductions in bacterial load and inflammation. Nonetheless, persistent challenges including antibiotic resistance, high treatment costs, and patient data privacy concerns continue to complicate progress. A deeper understanding of periodontitis reveals its impact as extending well beyond oral health, necessitating continued cross-disciplinary collaboration.

Introduction

Periodontal diseases encompass a wide range of inflammatory conditions that compromise the periodontium — the complex of tissues that support and surround the teeth. While gingivitis represents the most reversible form of periodontal disease, more advanced conditions such as chronic periodontitis, aggressive periodontitis, and peri-implantitis can result in irreversible tissue destruction. These conditions are broadly associated with a negative shift in the subgingival microbiome, producing maladaptive host-microbe interactions that trigger immune dysregulation

and progressive tissue breakdown. Understanding the classification and underlying mechanisms of these conditions is therefore foundational to the interpretation of the research discussed in this paper.

Significant advancements in diagnostic technologies — including radiographic imaging, salivary biomarker analysis, and quantitative molecular assays — have enabled clinicians to more accurately diagnose periodontal conditions and monitor disease progression over time. Despite these advances, important ethical challenges persist, including concerns about antibiotic resistance and the equitable accessibility of advanced diagnostic and treatment options. This paper examines the classification of periodontal diseases, their systemic connections, current and emerging diagnostic approaches, and established treatment modalities, while critically addressing the ethical dimensions that shape research and clinical practice in this field.

Discussion

Classification of Periodontal Diseases: Gingivitis, Chronic Periodontitis, Aggressive Periodontitis, and Peri-Implantitis

Periodontal diseases represent a group of inflammatory conditions affecting the supporting structures of the teeth, and their accurate classification is essential in clinical practice as it provides the framework for precise diagnosis, treatment planning, and prognosis assessment. Among the primary entities, gingivitis is the most prevalent form of periodontal disease, affecting up to 70–90% of adolescents worldwide (Armitage et al., 2017). Caused by dental plaque accumulation and modified by factors such as hormonal fluctuations, certain medications, and immune compromise, gingivitis manifests clinically as gingival erythema, edema, and bleeding on probing (BOP). Critically, gingivitis remains reversible with effective oral hygiene and professional care, distinguishing it from the more destructive forms of periodontitis.

Chronic periodontitis (CP) is the most prevalent destructive form of periodontal disease in adults, characterized by progressive loss of periodontal ligament (PDL) attachment and alveolar bone, resulting in pocket formation, gingival recession, and eventual tooth mobility (Singh, 2013). Because the periodontal pockets that form as gums pull away from the teeth can harbor significantly greater bacterial growth, the condition creates a self-reinforcing cycle of infection and tissue loss that may ultimately result in tooth loss if left untreated. Aggressive periodontitis (AgP) and peri-implantitis (PI) present distinct clinical and microbiological characteristics: AgP is marked by rapid attachment loss often disproportionate to local irritants, while PI involves inflammatory changes in the soft and hard tissues surrounding dental implants. Each entity requires a tailored

approach to diagnosis and management.

Periodontal-Systemic Connections: Cardiovascular Disease and Alzheimer's Disease

Emerging evidence has established meaningful links between periodontal disease and systemic conditions affecting the heart and brain. Individuals with periodontitis frequently present with elevated levels of systemic inflammatory markers such as C-reactive protein (CRP) and interleukin-6 (IL-6), which are known to damage blood vessel walls and increase the risk of myocardial infarction and stroke (Liccardo et al., 2019; D'Aiuto et al., 2019). A recent systematic review found that individuals with periodontitis are approximately 20% more likely to develop cardiovascular conditions compared to periodontally healthy individuals, with stroke risk appearing particularly elevated (Journal of Pharmacy & Bioallied Sciences, 2023).

The neurological dimension of this systemic relationship is equally compelling. Porphyromonas gingivalis, a key periodontal pathogen, has been detected in brain tissue samples from patients diagnosed with Alzheimer's disease, suggesting that oral bacterial infection may contribute to neuroinflammation and the accumulation of harmful proteins such as amyloid-beta (Zhang et al., 2025). Complementing these findings, a large national cohort study from Taiwan found that individuals with long-term periodontal disease face a 70.7% increased likelihood of developing Alzheimer's disease over time. Together, these data support the emerging view that periodontitis drives widespread systemic inflammation and bacteremia — contributing not only to cardiovascular risk but also to neurodegeneration — and underscore the importance of oral health as a component of overall systemic health management.

Diagnostics: Radiographic Imaging and Salivary Biomarker Analysis

A range of diagnostic modalities are available for the assessment of periodontal disease, each contributing distinct information to clinical decision-making. The standard periodontal examination involves measuring probing pocket depths (PPD), assessing bleeding on probing (BOP), and evaluating clinical attachment loss (CAL) — collectively enabling clinicians to differentiate between gingivitis, periodontitis, and stable periodontal conditions (Giannobile, 2012). Radiographic techniques such as bitewing and periapical X-rays complement the clinical examination by revealing alveolar bone loss and confirming disease extent. Salivary diagnostics represent a non-invasive adjunct capable of detecting microbial pathogens and host-response biomarkers including interleukin-1β (IL-1β), matrix metalloproteinase-8 (MMP-8), and tumor necrosis factor-alpha (TNF-α), as well as tissue breakdown products — allowing for real-time monitoring of disease activity, though questions surrounding widespread adoption and

cost-effectiveness remain.

Advanced molecular diagnostic methods have further enhanced the precision of periodontal assessment. Quantitative polymerase chain reaction (qPCR) enables rapid identification of microbial signatures and antibiotic resistance genes within clinical samples, delivering results within approximately three hours — a turnaround suited to routine dental practice to guide prescribing decisions before treatment is finalized (Manoil et al., 2024). This approach has demonstrated sensitivity and specificity exceeding 85–90% across multiple validation studies, making it a clinically valuable tool for identifying pathogenic species and informing targeted antimicrobial therapy. Classical bacterial culture techniques also continue to contribute through antibiotic susceptibility testing, though they are increasingly complemented by these faster molecular platforms.

Treatment Approaches: Antimicrobial Therapy and Surgical Interventions

Antimicrobial therapy constitutes a cornerstone of periodontal disease management alongside mechanical debridement. Systemic antibiotics including tetracyclines, metronidazole, and amoxicillin have been shown to suppress key periodontal pathogens effectively. Local delivery systems — such as tetracycline fibers, minocycline microspheres, and chlorhexidine chips — allow high concentrations of antimicrobials to be delivered directly to the periodontal pocket while minimizing systemic side effects (Loesche, 1999). The combination of metronidazole and amoxicillin has been associated with an additional attachment gain of approximately 1.0–1.5 mm beyond that achieved by mechanical treatment alone, while tetracycline therapy has demonstrated a 70–80% reduction in target pathogens (Loesche, 1999).

Scaling and root planing (SRP) — the foundational mechanical treatment — has been shown to reduce probing pocket depths by approximately 2.2–2.3 mm in moderate pockets of 4–6 mm, reflecting measurable clinical improvement. However, contemporary research has highlighted the superior antimicrobial efficacy of adjunctive povidone-iodine irrigation: when combined with SRP, this irrigant achieved a 95% reduction in periodontal pathogens, compared to only 6–13% pathogen reduction with SRP alone (Slots, 2002). Systemic antibiotic combinations — particularly metronidazole with amoxicillin, or metronidazole with ciprofloxacin — have demonstrated the capacity to achieve near-elimination of Porphyromonas gingivalis in treated patients. Collectively, the evidence supports substantially greater quantifiable improvements when mechanical therapy is combined with systemic antibiotics and antimicrobial irrigants such as povidone-iodine or sodium hypochlorite.

Ethics, Discussion, and Limitations

Several prominent ethical challenges accompany the research advancements discussed in this paper. The widespread use of systemic antibiotics in periodontal therapy raises significant concerns about antimicrobial resistance — a global public health threat that necessitates judicious prescribing practices and ongoing surveillance. Affordability and accessibility present additional ethical barriers: advanced treatment modalities such as local drug delivery systems, photodynamic therapy, and regenerative surgical procedures carry substantial costs that place them beyond the reach of many patients, particularly those in underserved communities. Scientists and clinicians bear a shared responsibility to develop and advocate for cost-effective clinical solutions that do not exacerbate existing health disparities.

Informed consent and patient autonomy are equally central to ethical periodontal care. Patients enrolled in research studies or receiving experimental antibiotic regimens must be provided with thorough, comprehensible information about proposed treatments, potential risks, and alternatives — as well as appropriate post-treatment disclosure. Concerns about data privacy also merit careful attention: in an era of rapidly advancing biomedical technologies, cases involving data breaches, unauthorized use of patient samples, or secondary analysis without explicit consent have raised important questions about transparency. Some diagnostic companies reserve the right to use anonymized patient data for algorithm development or commercial purposes, underscoring the need for robust regulatory frameworks that protect patient confidentiality and autonomy throughout the research and clinical pipeline.

Conclusion

Periodontal diseases represent a complex spectrum of inflammatory conditions that compromise the supporting structures of the teeth and carry implications that extend well beyond oral health. Understanding the classification of these conditions — encompassing gingivitis, chronic periodontitis, aggressive periodontitis, and peri-implantitis — is essential for accurate diagnosis, targeted treatment, and meaningful long-term prognosis. Research evidence has increasingly established that periodontal disease contributes to systemic inflammatory burden, with significant implications for the management of cardiovascular disease and neurodegenerative conditions such as Alzheimer's disease.

Advancements in diagnostic techniques — including radiographic imaging, salivary biomarker analysis, and qPCR-based microbial detection — have meaningfully improved clinicians' ability to

identify disease severity and microbial risk with greater precision, with sensitivity and specificity rates reaching 85–90% in validation studies. Treatment strategies combining mechanical debridement with antimicrobial agents and surgical interventions have demonstrated substantial pathogen reduction and clinical attachment gains. Looking ahead, the field must continue to address the ethical challenges of antibiotic stewardship, equitable access, and patient data protection, ensuring that the considerable scientific progress in periodontal research translates into safe, accessible, and effective care for all populations.

References

Armitage, G. C. (2017). Periodontal diagnoses and classification of periodontal diseases. *Periodontology 2000, 34*(1), 9–21.

D'Aiuto, F., et al. (2019). Periodontitis and systemic diseases: A record of discussions of working group 4 of the Joint EFP/AAP Workshop on Periodontitis and Systemic Diseases. *Journal of Clinical Periodontology, 40*(S14), S114–S119.

Giannobile, W. V. (2012). Salivary diagnostics for periodontal diseases. *Journal of the American Dental Association, 143*(10 Suppl), 6S–10S.

Journal of Pharmacy & Bioallied Sciences. (2023). Periodontal disease and cardiovascular risk: A systematic review. *Journal of Pharmacy & Bioallied Sciences, 15*(Suppl 1).

Liccardo, D., et al. (2019). Periodontal disease: A risk factor for diabetes and cardiovascular disease. *International Journal of Molecular Sciences, 20*(6), 1414.

Loesche, W. J. (1999). Antimicrobial chemotherapy in the treatment of periodontal disease. *Periodontology 2000, 20*(1), 158–189.

Manoil, D., et al. (2024). Rapid qPCR-based identification of periodontal pathogens and antibiotic resistance genes in routine dental practice. *Journal of Clinical Periodontology*.

Singh, A. (2013). Gingivitis — a silent disease. *Journal of Dental Sciences and Research, 4*(2), 1–6.

Slots, J. (2002). Selection of antimicrobial agents in periodontal therapy. *Journal of Periodontal Research, 37*(5), 389–398.

Stathopoulou, P., et al. (2017). Periodontal diseases. *ResearchGate / Faculty Dental Journal*. https://www.researchgate.net/publication/318158042

Zhang, J., et al. (2025). Porphyromonas gingivalis and neuroinflammation in Alzheimer's disease: Evidence and mechanisms. *Premier Journal of Dentistry*. https://premierscience.com/wp-content/uploads/2025/05/pjd-25-864.pdf

Taiwan National Health Insurance Research Database Cohort Study. (2017). Long-term periodontal disease and risk of Alzheimer's disease: A population-based cohort study. *Alzheimer's & Dementia*.